Sangamo Therapeutics Inc
Nyitva
SzektorEgészségügy
0.17
Áttekintés
Árfolyamváltozás megosztása
24 óra
Minimum
0.17
Maximum
0.17
Bevétel | -2.5M -37M |
|---|---|
Értékesítés | 14M 14M |
Egy részvényre jutó nyereség | -0.111 |
Profit margin | -262.996 |
Munkavállalók | 142 |
EBITDA | 10M -23M |
Ajánlások | Vétel |
|---|---|
12 hónapos előrejelzés | +4900% upside |
Piaci kapitalizáció | -51M 74M |
|---|---|
Előző nyitás | 0.17 |
Előző zárás | 0.17 |
Technikai pontszám
By Trading Central
Bizalom
Strong Bearish Evidence
Sangamo Therapeutics Inc Chart
A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.
Kapcsolódó hírek
Társak összehasonlítása
Árváltozás
Sangamo Therapeutics Inc Előrejelzés
Célár
By TipRanks
4900% elmozdulás felfelé
12 hónapos előrejelzés
Átlag 6 USD 4900%
Magas 10 USD
Alacsony 2 USD
2 Wall Street elemző 12 hónapos célárain alapulva a(z)Sangamo Therapeutics Inc termékhez az elmúlt 3 hónapban.
Pénzügyek
$
Rólunk Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.
